Evidence map›Paper›PMID 26327283›Full record

ArticlePloS one2015

The Influence of Sub-Unit Composition and Expression System on the Functional Antibody Response in the Development of a VAR2CSA Based Plasmodium falciparum Placental Malaria Vaccine.

Morten A Nielsen, Mafalda Resende, Willem A de Jongh, Sisse B Ditlev, Benjamin Mordmüller, Sophie Houard, Nicaise Tuikue Ndam, Mette Ø Agerbæk, Mette Hamborg, Achille Massougbodji and 11 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
7.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 46 citations in OpenAlex.

  1. First-in-human, Randomized, Double-blind Clinical Trial of Differentially Adjuvanted PAMVAC, A Vaccine Candidate to Prevent Pregnancy-associated Malaria.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2019
    Trial
  2. Article
  3. Article
  4. Article
  5. Expression of Large Full-Length PfEMP1 Proteins in HEK293 Cells.Methods in molecular biology (Clifton, N.J.) · 2022
    Article
  6. Article
  7. Review
  8. Frontiers in immunology · 2021
    Article
  9. Review
  10. VAR2CSA-Mediated Host Defense Evasion ofFrontiers in immunology · 2020
    Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 12 institutions in 5 countries.

Morten A NielsenCentre for Medical Parasitology at Department of Immunology and Microbiology, Faculty of Health and Medical Science, University of Copenhagen, and Department of Infectious Diseases, Copenhagen University Hospital (Rigshospitalet), Copenhagen, Denmark.
Mafalda ResendeCentre for Medical Parasitology at Department of Immunology and Microbiology, Faculty of Health and Medical Science, University of Copenhagen, and Department of Infectious Diseases, Copenhagen University Hospital (Rigshospitalet), Copenhagen, Denmark.
Willem A de JonghExpreS2ion Biotechnologies, SCION-DTU Science Park, Hørsholm, Denmark.
Sisse B DitlevCentre for Medical Parasitology at Department of Immunology and Microbiology, Faculty of Health and Medical Science, University of Copenhagen, and Department of Infectious Diseases, Copenhagen University Hospital (Rigshospitalet), Copenhagen, Denmark.
Benjamin MordmüllerEberhard Karls Universität Tübingen, Institut für Tropenmedizin, Tübingen, Germany, and Centre de Recherches Médicales de Lambaréné, Lambaréné, Gabon.
Sophie HouardEuropean Vaccine Initiative, Universitäts Klinikum Heidelberg, Heidelberg, Germany.
Nicaise Tuikue NdamInstitut de Recherche pour le Développement, UMR216 Mère et enfant face aux infections tropicales, Paris, France; PRES Sorbonne Paris Cité, Université Paris Descartes, Paris, France.
Mette Ø AgerbækCentre for Medical Parasitology at Department of Immunology and Microbiology, Faculty of Health and Medical Science, University of Copenhagen, and Department of Infectious Diseases, Copenhagen University Hospital (Rigshospitalet), Copenhagen, Denmark.
Mette HamborgCentre for Medical Parasitology at Department of Immunology and Microbiology, Faculty of Health and Medical Science, University of Copenhagen, and Department of Infectious Diseases, Copenhagen University Hospital (Rigshospitalet), Copenhagen, Denmark.
Achille MassougbodjiFaculté des Sciences de la Santé de l'Université d'Abomey-Calavi, Centre d'étude et de recherche sur le paludisme associé à la grossesse et à l'enfance, Cotonou, Bénin.
Saddou IssifouFaculté des Sciences de la Santé de l'Université d'Abomey-Calavi, Centre d'étude et de recherche sur le paludisme associé à la grossesse et à l'enfance, Cotonou, Bénin.
Anette StrøbækExpreS2ion Biotechnologies, SCION-DTU Science Park, Hørsholm, Denmark.
Lars PoulsenExpreS2ion Biotechnologies, SCION-DTU Science Park, Hørsholm, Denmark.
Odile LeroyEuropean Vaccine Initiative, Universitäts Klinikum Heidelberg, Heidelberg, Germany.
Peter G KremsnerEberhard Karls Universität Tübingen, Institut für Tropenmedizin, Tübingen, Germany, and Centre de Recherches Médicales de Lambaréné, Lambaréné, Gabon.
Jean-Philippe ChippauxInstitut de Recherche pour le Développement, UMR216 Mère et enfant face aux infections tropicales, Paris, France; PRES Sorbonne Paris Cité, Université Paris Descartes, Paris, France; Faculté des Sciences de la Santé de l'Université d'Abomey-Calavi, Centre d'étude et de recherche sur le paludisme associé à la grossesse et à l'enfance, Cotonou, Bénin.
Adrian J F LutyInstitut de Recherche pour le Développement, UMR216 Mère et enfant face aux infections tropicales, Paris, France; PRES Sorbonne Paris Cité, Université Paris Descartes, Paris, France; Faculté des Sciences de la Santé de l'Université d'Abomey-Calavi, Centre d'étude et de recherche sur le paludisme associé à la grossesse et à l'enfance, Cotonou, Bénin.
Philippe DeloronInstitut de Recherche pour le Développement, UMR216 Mère et enfant face aux infections tropicales, Paris, France; PRES Sorbonne Paris Cité, Université Paris Descartes, Paris, France.
Thor G TheanderCentre for Medical Parasitology at Department of Immunology and Microbiology, Faculty of Health and Medical Science, University of Copenhagen, and Department of Infectious Diseases, Copenhagen University Hospital (Rigshospitalet), Copenhagen, Denmark.
Charlotte DyringExpreS2ion Biotechnologies, SCION-DTU Science Park, Hørsholm, Denmark.
Ali SalantiCentre for Medical Parasitology at Department of Immunology and Microbiology, Faculty of Health and Medical Science, University of Copenhagen, and Department of Infectious Diseases, Copenhagen University Hospital (Rigshospitalet), Copenhagen, Denmark.
University of Copenhagen · DKExpreS2ion Biotechnologies (Denmark) · DKUniversité d'Abomey-Calavi · BJCentre de Recherche Médicales de Lambaréné · GACopenhagen University Hospital · DKDélégation Paris 5 · FRHeidelberg University · DEInstitut de Recherche pour le Développement · FRRigshospitalet · DKUniversité Paris Cité · FRUniversity of Tübingen · DEVienna Vaccine Safety Initiative · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The disease caused by Plasmodium falciparum (Pf) involves different clinical manifestations that, cumulatively, kill hundreds of thousands every year. Placental malaria (PM) is one such manifestation in which Pf infected erythrocytes (IE) bind to chondroitin sulphate A (CSA) through expression of VAR2CSA, a parasite-derived antigen. Protection against PM is mediated by antibodies that inhibit binding of IE in the placental intervillous space. VAR2CSA is a large antigen incompatible with large scale recombinant protein expression. Vaccines based on sub-units encompassing the functionally constrained receptor-binding domains may, theoretically, circumvent polymorphisms, reduce the risk of escape-mutants and induce cross-reactive antibodies. However, the sub-unit composition and small differences in the borders, may lead to exposure of novel immuno-dominant antibody epitopes that lead to non-functional antibodies, and furthermore influence the folding, stability and yield of expression. Candidate antigens from the pre-clinical development expressed in High-Five insect cells using the baculovirus expression vector system were transitioned into the Drosophila Schneider-2 cell (S2) expression-system compliant with clinical development. The functional capacity of antibodies against antigens expressed in High-Five cells or in S2 cells was equivalent. This enabled an extensive down-selection of S2 insect cell-expressed antigens primarily encompassing the minimal CSA-binding region of VAR2CSA. In general, we found differential potency of inhibitory antibodies against antigens with the same borders but of different var2csa sequences. Likewise, we found that subtle size differences in antigens of the same sequence gave varying levels of inhibitory antibodies. The study shows that induction of a functional response against recombinant subunits of the VAR2CSA antigen is unpredictable, demonstrating the need for large-scale screening in order to identify antigens that induce a broadly strain-transcending antibody response.

Indexed as

AnimalsAntibody FormationAntigens, ProtozoanCross ReactionsDrosophila melanogasterFemaleHumansMalaria, FalciparumMalaria VaccinesPlacentaPlasmodium falciparumPregnancyProtein EngineeringRecombinant ProteinsAntigens, ProtozoanMalaria VaccinesRecombinant ProteinsVAR2CSA protein, Plasmodium falciparum

Identifiers

PMID26327283
PMCPMC4556615
OpenAlexW1905770058

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.